PCM
RPRX icon

Pavaki Capital Management’s Royalty Pharma RPRX Stock Holding History

Pavaki Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Hold
44,000
– – 0.86% 25
2026
Q1 		$2.11M Hold
44,000
– – 0.9% 24
2025
Q4 		$1.7M Buy
+44,000
New +$1.68M 0.67% 30

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Pavaki Capital Management's RPRX Position: Q2 2026 in Review

Pavaki Capital Management held its Royalty Pharma (RPRX) position steady in Q2 2026 at 44,000 shares worth $2.47M. The position accounts for 0.86% of the portfolio, ranked #25.

Pavaki Capital Management first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 607 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Pavaki Capital Management held 44,000 shares of Royalty Pharma worth $2.47M as of Q2 2026.
  • Pavaki Capital Management left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.86% of Pavaki Capital Management's portfolio in Q2 2026, its #25 holding.
  • Pavaki Capital Management first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 607 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.